Moleculin Biotech: Annamycin Combo Shows Promise in Pancreatic Cancer Models

Moleculin Biotech, Inc. announced new preclinical data demonstrating that its lead drug candidate, Annamycin (naxtarubicin), when combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The combination therapy outperformed either agent alone, suggesting a potential new approach for treating pancreatic cancer, a disease often unresponsive to immune checkpoint inhibitors. The data also indicate that Annamycin achieves higher pancreatic tissue exposure than doxorubicin and enhances the infiltration of immune T cells, which are crucial for its antitumor activity. Moleculin plans to initiate an investigator-sponsored clinical trial for Annamycin in pancreatic cancer in 2027.